

1 **Full title:** High prevalence of asymptomatic and sub-patent *Plasmodium falciparum* infections in
2 Urban Bouaké, Côte d'Ivoire, but no *hrp2* deletions: Implications for Malaria Control

3

4 **Short title:** The hidden burden of malaria infections in urban Côte d'Ivoire

5

6 **Author names:** André Barembaye Sagna^{1,2,3}, Yilekal Gebre², Claudia Abigail Vera-Arias²,

7 Dipomin François Traoré^{3,4}, Bertin N'cho Tchekoi³, Serge Brice Assi⁵, Amnan Alphonsine

8 Koffi³, Christophe Rogier^{6,7}, Franck Remoue¹, Cristian Koepfli²

9

10 **Affiliations**

11 1) MIVEGEC, University of Montpellier, IRD, CNRS, Montpellier, France

12 2) Department of Biological Sciences and Eck Institute for Global Health, University of Notre,
13 Dame, Notre Dame, IN, USA

14 3) Institut Pierre Richet, Institut National de la Santé Publique, Bouaké, Côte d'Ivoire

15 4) Université Alassane Ouattara, Bouaké, Côte d'Ivoire

16 5) Programme National de Lutte Contre le Paludisme en Côte d'Ivoire, Ministère de la Santé et de
17 l'Hygiène Publique, Abidjan, Côte d'Ivoire.

18 6) Primum vitare, Paris, France

19 7) Institut Pasteur de Madagascar, Antananarivo, Madagascar

20

21 **Corresponding authors:**

22 André B. SAGNA, andre.sagna@ird.fr and Cristian Koepfli, ckoepfli@nd.edu

23 **Abstract:**

24 Asymptomatic *Plasmodium falciparum* infections are common in endemic settings, yet
25 diagnosing these infections remains challenging because they are often below the limit of
26 detection of conventional light microscopy (LM) or rapid diagnostic tests (RDTs). Deletions of
27 the *hrp2/3* gene, encoding the protein detected by the most sensitive class of RDTs, present a
28 further threat. In this study, the prevalence of asymptomatic and sub-patent *P. falciparum*
29 infections was characterized in the rainy season in the city of Bouaké, Central Côte d'Ivoire.
30 A cross-sectional survey was conducted in nine neighborhoods of Bouaké, Côte d'Ivoire, in
31 2016. Matched LM, RDTs, and *varATS* qPCR, were used to determine the prevalence of *P.*
32 *falciparum* infections and to compare the performance of the different diagnostic methods. *P.*
33 *falciparum* *hrp2/3* deletions were typed by digital PCR. Among 2313 individuals, malaria
34 prevalence was 10.8% by microscopy, 13.0% by RDT, 35.1% by qPCR, and 37.3% (863/2313)
35 when all three methods were combined. 96.4% (832/863) of individuals with *P. falciparum*
36 infections did not report a recent fever. 57.1% (493/863) of infections were sub-patent. The
37 prevalence was highly heterogeneous across the neighborhoods, ranging from 15% to 55.2%, and
38 differed among age groups (<5 years: 17.7%, 5-14 years: 42.7%, ≥15 years: 35.9%). Compared
39 to *varATS* qPCR, LM and RDT had a low sensitivity of 24.3% and 34.2%, respectively, although
40 both methods were highly specific (>96%). Sub-microscopic malaria infections were more
41 prevalent in ≥15-year-olds (69.9%, 349/499) and in the neighborhood of Dar es Salam (75.9%,
42 44/58). No *hrp2* deletions were observed, and two samples carried *hrp3* deletion/wild-type mixed
43 infections. The high prevalence of asymptomatic and sub-patent infections prompts the
44 implementation of strategies targeting these parasite reservoirs to achieve reductions in malaria
45 burden in this high-transmission city of Côte d'Ivoire.

46 **Introduction**

47 The overall number of malaria infections is undeniably much higher than the estimated 241
48 million clinical cases (1) in 2020, owing to the large proportion of asymptomatic infections
49 among people living in endemic areas (2). Asymptomatic (or subclinical) malaria infection refers
50 to malarial parasitemia of any density in the absence of fever or other acute symptoms in
51 individuals who have not received recent antimalarial treatments (3). While some asymptomatic
52 infections may have parasitemia levels that are detectable by light microscopy (LM) or rapid
53 diagnostic tests (RDTs), others can only be detected by molecular methods and are termed sub-
54 patent infections (4). Asymptomatic and sub-patent individuals remain untreated in countries
55 where control focuses on clinical malaria cases and serve as reservoirs for onward transmission
56 (5,6). Quantifying the extent of submicroscopic infections and the underlying true prevalence of
57 parasites in different settings is central to understanding the dynamics of malaria transmission
58 and adapting control measures accordingly.

59 The asymptomatic reservoir presents a major challenge for control, with up to 95% of
60 transmission stemming from asymptomatic carriers (7–9). Numerous approaches are currently
61 being trialed or implemented to shrink the asymptomatic reservoir, such as mass screening and
62 treatment (10,11), reactive case detection (12), focal mass drug administration (13), or seasonal
63 malaria chemoprophylaxis (14).

64 The success of control strategies for conducting active screening for infections relies heavily on
65 the sensitivity of the diagnostic test used. These programs typically use RDTs, the only
66 diagnostic method that can readily be used away from health centers. Yet, the sensitivity of RDTs
67 is limited. Compared to highly sensitive PCR, RDTs often miss more than half of all infections

68 (15). The most sensitive RDTs for *P. falciparum* detect the HRP2 and HRP3 proteins. Deletions
69 of the *hrp2/3* genes result in false-negative RDTs, even if parasite density is high. Initially
70 reported in Peru (16), the frequency of *hrp2/3* is high in the Horn of Africa (17–20), and deletions
71 were also reported from Ghana (21,22). Surveillance of *hrp2/3* is needed to decide whether
72 HRP2-based RDTs can be used for *P. falciparum* diagnosis.

73 The epidemiology of urban malaria in Côte d’Ivoire is not well documented, with few studies
74 conducted in the southern (23–25) and northern parts of the country (26). These studies found a
75 high prevalence of infection by microscopy, ranging from 12% in the north to more than 60% in
76 the south. This difference in infection prevalence could mainly be explained by climatic factors.
77 The climate is tropical (Sub-Saharan) in the north with two main seasons, and equatorial in the
78 south with two rainy seasons and two dry seasons (27). Other factors such as age groups (5-14
79 years), traveling to rural areas, and agriculture practices have also been found to be risk factors
80 for malaria infections in urban areas (23–26).

81 Bouaké, in central Côte d’Ivoire, is the second-most populous city in the country, with more than
82 750,000 inhabitants in 2015. Like many cities in sub-Saharan Africa, urban agriculture is
83 widespread within and around the city to increase food security. This agricultural activity has
84 been shown to significantly impact malaria transmission with the creation of numerous larval
85 habitats and vector proliferation (28–30). Bouaké is a highly endemic area with >160,000 malaria
86 cases recorded each year (annual incidence >200 per 1000 inhabitants) and more than 100 deaths
87 (31). Bouaké suffered from an armed conflict and a sociopolitical crisis from 2000 to 2011,
88 leading to large population moves, environmental modifications, and interruption in the
89 implementation and/or maintenance of malaria control strategies for the whole period (32,33).

90 Following the crisis, the population has reinvested in the city and resettled in formerly abandoned
91 neighborhoods. Only a few epidemiological studies have been conducted in the city of Bouaké,
92 and the real burden of malaria is underestimated, with no published data available on the
93 prevalence of asymptomatic and submicroscopic malaria infections. Its characterization will help
94 the national malaria control program (NMCP) adapt control measures for a more efficient use of
95 limited resources.

96 The objectives of this study were to measure the burden of asymptomatic and sub-patent *P.*
97 *falciparum* infections by LM, RDT, and qPCR in the highly endemic city of Bouaké and to
98 investigate potential *P. falciparum* *hrp2* and/or *hrp3* deletion.

99 **Materials and Methods**

100 ***Ethical approval and source of funding***

101 Funding was provided by the French Initiative 5% and Expertise France, Grant N°12INI210. This
102 study followed the ethical principles recommended by the Edinburgh revision of the Declaration
103 of Helsinki and was approved by the Ethics Committee of the Ministry of Health of Côte d'Ivoire
104 (June 2015; No. 029/MSLS/CNER-dkn) and the University of Notre Dame Institutional Review
105 Board (18-08-4803). Before collecting samples, all participants over the age of 18 provided
106 written informed consent, as did the parent/guardian of each participant under the age of 18.

107 ***Study area and demographic data collection***

108 In Côte d'Ivoire, malaria transmission occurs all year round, with a peak during the rainy season.
109 The annual incidence rates vary between 100 and >500 cases per 1000 inhabitants, with more
110 than 80% of the whole Ivoirian population living in areas with an annual incidence rate ≥ 300 per
111 1000 inhabitants (31). Despite a national coverage of long-lasting insecticidal nets (LLINs)

112 estimated at 95% since 2015, the number of malaria-related cases has been increasing since 2016
113 from 3,754,504 to 7,295,068 cases in 2021 (34). The number of malaria-related deaths has
114 decreased during the same period, from 3,340 to 1,276 deaths.

115 The survey was conducted in three health districts of the city of Bouaké: Northwestern-Bouaké,
116 Northeastern-Bouaké, and Southern-Bouaké. All health districts had a high coverage rate (>80%)
117 of standard pyrethroid-based LLINs. This area has year-round malaria transmission, with a peak
118 during the wet season (April–October). *P. falciparum* is the dominant species identified in more
119 than 95% of malaria cases (35). The *Anopheles gambiae* species complex is the dominant vector
120 species, with *An. funestus* and *An. nili* also present. The local vector populations are highly
121 resistant to almost all classes of insecticides used for vector control (36,37).

122 A cross-sectional study was performed from August 1st to August 27th, 2016, in nine
123 neighborhoods of the city (three neighborhoods per health district): Dar-es-Salam,
124 Djezoukouamekro, and N’gattakro in Northwestern-Bouaké; Sokoura, Belle-ville, and Attienkro
125 in Northeastern-Bouaké; Kennedy, Air-France, and N’gouattanoukro in Southern-Bouaké. This
126 study was part of a large operational research project named PALEVALUT
127 (<http://www.mesamalaria.org/mesa-track/palevalut>), which aimed to evaluate the effectiveness of
128 malaria control resources currently deployed and identify the barriers to their effectiveness in five
129 different sub-Saharan countries (Benin, Cameroon, Côte d’Ivoire, Niger, and Madagascar). In
130 each selected neighborhood, 50 households were randomly selected, and all members who were
131 at home were invited to participate in the study. After enrollment, all households were geo-
132 located using GPS (Garmin, Switzerland) instruments with up to 5 m of accuracy. A socio-
133 demographic questionnaire was completed with the head of the family to collect information

134 about the sanitary conditions of the household and household characteristics (house type and
135 construction materials, bathroom type, access to public services, etc.). Information on age, sex,
136 history of fever, LLIN use, and knowledge of malaria was recorded for each participant.

137 ***Case definitions***

138 An asymptomatic malaria infection was defined as a *P. falciparum* positive test result in an
139 afebrile individual (temperature $\leq 37.5^{\circ}\text{C}$) at the time of sampling with no history of fever in the
140 previous 48 hours. A clinical malaria case was defined as a positive test result with a history of
141 fever or a temperature $> 37.5^{\circ}\text{C}$. Sub-patent infections were defined as infections that were only
142 positive by *varATS* qPCR.

143 ***Blood sample collection***

144 During the house visit, blood samples were collected from each study participant using a 1 mL
145 insulin syringe (Luer-Lok™, BD, Franklin Lakes, NJ, USA) to prepare thick and thin blood
146 smears (both thick and thin smears were collected on the same slide), one RDT, and two spots on
147 Whatman qualitative filter paper N°3. The remaining blood was poured into a 1.5-mL
148 microcentrifuge tube. At the laboratory, microcentrifuge tubes were centrifuged, and plasma was
149 removed and stored at -20°C . The red cell pellets were also stored at -20°C until DNA extraction.
150 All samples of each study participant were labeled with a unique code and stored accordingly
151 until use.

152 ***RDT-based diagnosis and treatment***

153 The Pf/HRP2-based RDT (Standard Diagnostics Inc.; Yongin, Republic of Korea) recommended
154 by the NMCP of Côte d'Ivoire was used in this study. This RDT is based on histidine-rich protein
155 2 (HRP2) detection and is specific to *P. falciparum* (Pf). All febrile individuals that tested

156 positive for RDT were treated with anti-malarials according to the national drug policy. Those
157 found positive by microscopy or qPCR were not treated because microscopy examination and
158 qPCR assays were not performed at the point of collection.

159 ***Microscopic examination***

160 Giemsa-stained peripheral blood smears were examined under a compound microscope
161 (Olympus CX21 LED) at 1000× magnification to detect malaria parasites by trained technicians.
162 Ring, trophozoite, or gametocyte stages were identified and assessed for parasite density
163 (parasites/μl blood) against 200 white blood cells (WBCs), and densities were calculated
164 considering an average of 8000 WBC/μl.

165 All positive slides and 10% of randomly chosen negative blood slides were cross-examined by
166 independent laboratory personnel as part of a standard protocol to monitor examination quality.
167 Microscopists who examined the participants' blood slides were not aware of the RDT results.

168 ***DNA extraction and qPCR detection of *P. falciparum* infections***

169 DNA was extracted from 100 μL of blood using the Genomic DNA Extraction Kit (Macherey-
170 Nagel, Düren, Germany) and eluted in 100 μL of elution buffer. 4 μL of extracted DNA was
171 screened for *P. falciparum* using ultrasensitive qPCR that amplifies a conserved region of the var
172 gene acidic terminal sequence (*varATS*) according to a previously published protocol (38). The
173 qPCR results were converted to parasites/μL using an external standard curve of ten-fold serial
174 dilutions (5-steps) of 3D7 *P. falciparum* parasites quantified by droplet digital PCR (ddPCR)
175 (39,40).

176 ****P. falciparum* hrp2/3 typing by digital PCR***

177 Samples positive for *P. falciparum* at a density of approximately >5 parasites/ μ L by *var*ATS
178 qPCR were typed for *hrp2* and *hrp3* deletion by dPCR (41). To this end, the assay was
179 successfully transferred from the BioRad QX 200 droplet digital PCR system to the Qiagen
180 QIAcuity dPCR system. Assay conditions were maintained as previously published (41). In this
181 assay, *hrp2* or *hrp3* and a control gene (*serine-tRNA ligase*) were quantified in a single tube with
182 very high specificity, thus providing highly accurate data on deletion status. The assay amplified
183 parts of *hrp2* exon 2 that encode for the antigen detected by the RDT.

184 ***Data analysis***

185 Field data were collected and stored using the Open Data Kit toolkit. Electronic data was
186 exported to MS Excel for analysis. A data summary was done using descriptive statistics.
187 Malaria prevalence was calculated for each diagnostic test (light microscopy and RDT) and
188 compared to the gold standard of *var*ATS qPCR using McNemar's or Cochran's test. The
189 comparison of malaria prevalence by age group, gender, neighborhood, symptoms, and LLIN use
190 was done using the Pearson χ^2 test or Fisher's exact test, as appropriate. Differences in parasite
191 densities between age groups were determined by ANOVA's Dunn's multiple comparisons test.
192 The limits of detection (LoD) of light microscopy (LM) and RDT, defined as the lowest parasite
193 density that would be detected with 95% probability, were determined by logistic regression
194 based on *var*ATS qPCR parasite density. Univariate and multivariate logistic regression models
195 were used to investigate the association between sub-patent malaria infections and risk factors.
196 Variables significant at a p-value of 0.30 in the univariate logistic regression were selected for the
197 multivariate logistic regression analysis model. For all statistical tests, a 5% level of significance
198 was used. Odds ratios with 95% confidence intervals (CI) were reported. All statistical analyses

199 were performed using Graph Pad Prism 9.5 (Graph Pad Software, San Diego, CA, USA) and
200 MedCalc 20.218 (MedCalc Software Ltd., Ostend, Belgium).

201 **Results**

202 **Study population demography**

203 Matched LM, RDT, and varATS qPCR data were available for 2313 individuals (Figure 1). The
204 median age was 18 years (interquartile range: 8-33). Females represented 57.2% of the study
205 population. The majority of individuals (60.4%) reported using an LLIN within the last 15 days,
206 which varied between neighborhoods (Table 1).

207 **Table 1: Social demographic and clinical characteristics of the study population: Bouaké,**
 208 **Côte d’Ivoire, 2016**

Characteristics	Participants (N=2313)
Age	
<5 years	345 (14.9%)
5-14 years	646 (27.9%)
≥15 years	1322 (57.2%)
Median age [interquartile range]	18.0 [8.0 - 33.0]
Female sex	1324 (57.2%)
Neighborhood	
Attienkro	310 (13.4%)
Belle-ville	315 (13.6%)
Sokoura	320 (13.8%)
Dar es Salam	257 (11.1%)
Djézoukouamékro	192 (08.3%)
Ngattakro	220 (09.5%)
Kennedy	173 (07.5%)
Air-France	204 (08.8%)
Ngouatanoukro	322 (13.9%)
Bed net use (last two weeks, n=2090)	
Every night	1263 (60.4%)
Sometimes or never	827 (39.6%)
Clinical characteristics	
Cases of fever	66 (2.8%)
Positive (with RDT)	300 (13.0%)
Positive (with microscopy)	249 (10.8%)
Positive (with <i>varATS</i> qPCR)	812 (35.1%)
Total positive	863 (37.3%)
Total clinical malaria (with fever)	31/66 (47.0%)
Total asymptomatic cases (without fever)	832/863 (96.4%)
Total sub-patent infections	493/863 (57.1%)
Symptomatic, sub-patent infections (with fever)	9/493 (1.8%)
Asymptomatic, sub-patent infections (without fever)	484/493 (98.2%)
Symptomatic, sub-patent infections (with fever) among all positives	9/863 (1.0%)
Asymptomatic, sub-patent infections (without fever) among all positives	484/863 (56.1%)

209 **Symptomatic, asymptomatic and sub-patent *P. falciparum* infections**

210 Among the full study population, 37.3% (863/2313) of participants were diagnosed positive by
211 LM, RDT, and qPCR combined (**Table 1**). **Figure 2** shows the distribution of *P. falciparum*
212 infections according to the three diagnostic methods used. The prevalence of *P. falciparum*
213 infections varied significantly according to the diagnostic method and was 10.8% (249/2313) by
214 LM, 13% (300/2313) by RDT, and 35.1% (812/2313) by qPCR (Cochran's $Q=823.9$, $DF=2$, $p<$
215 0.001). Of all *P. falciparum* infections, 96.4% (832/863) were classified as asymptomatic and
216 57.1% (493/863) as sub-patent (**Table 1, Figure 2**). Sixty-six (66) persons reported fever or a
217 history of fever within 48 hours, of which 31 (47%) were positive by LM, RDT, and qPCR
218 combined. The number of clinical malaria cases was variable depending on the diagnostic
219 method and was 17 by LM, 20 by RDT, and 27 by qPCR. Nine clinical malaria cases were
220 missed by both LM and RDT (**Figure 2**).

221 *P. falciparum* infection prevalence differed significantly among age groups, sex, neighborhoods,
222 and symptoms (**Table 2**). The prevalence of infections peaked in 5–14-year-olds (irrespective of
223 diagnostic method, all $p<0.0001$). Although malaria prevalence tended to be lower in individuals
224 ≥ 15 years compared to <5 years by LM and RDT, it was 2-fold higher in individuals ≥ 15 years
225 compared to <5 years by qPCR. Prevalence was higher in males compared to females by all three
226 diagnostic methods (all $p<0.05$; **Table 2**). The prevalence was highest in Attienkro, health
227 district of Northwestern Bouaké (28.7% by LM, 19.0% by RDT, and 55.2% by qPCR). The
228 lowest prevalence by LM (1.6%) and qPCR (15.0%) was recorded in Sokoura, health district of
229 Northwestern Bouaké, and by RDT (5.1%) in Dar es Salam, health district of Northeastern
230 Bouaké (**Table 2**). Aside from the neighborhood of Attienkro, health district of Northeastern

231 Bouaké, where prevalence was higher for LM (28.7%) compared to RDT (19.0%, $p < 0.001$), all
232 neighborhoods displayed an equal or higher prevalence by RDT as compared to LM. qPCR
233 detected higher numbers of infections than LM or RDT in all neighborhoods (all $p < 0.001$).
234 The prevalence of *P. falciparum* infections was significantly higher in individuals who reported
235 fever or a history of fever within 48 hours compared to afebrile individuals by LM and RDT (all
236 $p < 0.0001$), but not by qPCR ($p = 0.316$).
237 The overall parasite density expressed as geometric mean parasite density by qPCR was 40
238 parasites/ μL (95% CI: 33.7-47.5, **Figure 3A**). Individuals who were positive by all three tests had
239 a significantly higher parasite density (856.8 parasites/ μL ; 95% CI: 707.3–1,038) than those who
240 were positive by *varATS* qPCR only (13.7 parasites/ μL ; 95% CI: 11.4–16.3) ($p < 0.0001$) (**Figure**
241 **3A**). Parasite density varied significantly by age group and was lower in ≥ 15 -year-olds (27.2
242 parasites/ μL ; 95% CI: 22.2-33.5) compared to < 5 -year-olds (73.5 parasites/ μL ; 95% CI: 36.9-
243 146.2; $p = 0.004$) and 5-14-year-olds (76.5 parasites/ μL ; 95% CI: 55.9-104.7; $p < 0.001$, **Figure**
244 **3B**).

245 **Table 2: Prevalence of *P. falciparum* infections by microscopy, RDT and varATS qPCR (N=2313).**

Characteristics		N	Tested positive by LM	<i>p</i> -value	Tested positive by RDT	<i>p</i> -value	Tested positive by qPCR	<i>p</i> -value
Age group	<5	345	30 (8.7%)	<0.0001	42 (12.2%)	<0.0001	61 (17.7%)	<0.0001
	5-14	646	118 (18.3%)		153 (23.7%)		276 (42.7%)	
	≥15	1322	101 (7.6%)		105 (7.9%)		475 (35.9%)	
Gender	Male	989	123 (12.4%)	0.026	148 (15.0%)	0.014	376 (38.0%)	0.012
	Female	1324	126 (9.5%)		152 (11.5%)		436 (32.9%)	
Neighborhood	Attienkro	310	89 (28.7%)	<0.0001	59 (19.0%)	<0.0001	171 (55.2%)	<0.0001
	Belle-ville	315	29 (9.2%)		39 (12.4%)		103 (32.7%)	
	Sokoura	320	5 (1.6%)		16 (8.4%)		48 (15.0%)	
	Dar es Salam	257	9 (3.5%)		13 (5.1%)		58 (22.6%)	
	Djézoukouamékro	192	27 (14.1%)		36 (18.8%)		94 (49.0%)	
	Ngattakro	220	16 (7.3%)		17 (7.7%)		65 (29.5%)	
	Kennedy	173	13 (7.5%)		26 (15.0%)		69 (39.9%)	
	Air-France	204	22 (10.8%)		36 (17.6%)		81 (39.7%)	
	Ngouatanoukro	322	39 (12.1%)		58 (18.0%)		123 (38.2%)	
Symptoms	Febrile	66	17 (25.8%)	<0.0001	20 (30.3%)	<0.0001	27 (40.9%)	0.316
	Afebrile	2247	232 (10.3%)		280 (12.5%)		785 (34.9%)	
Bed net use (last two weeks)	Every night	1263	147 (11.6%)	0.378	166 (13.1%)	0.854	460 (36.4%)	0.727
	Sometimes/never	827	86 (10.4%)		111 (13.4%)		295 (35.7%)	

246

247 ***Specificity and sensitivity of microscopy and RDT***

248 Compared to the gold standard qPCR, the sensitivity of RDT and LM was low at 34.24% (95%
 249 CI: 30.97–37.61) and 24.34% (95% CI: 21.47–27.49), respectively (**Table 3**). However, both
 250 methods were highly specific: 98.53% (95% CI: 97.79–99.08) for RDT, and 96.60% (95% CI:
 251 95.56–97.46) for LM. The measurement of agreement (Kappa) was high between RDT and
 252 microscopy (60.6%, $p < 0.001$).

253 **Table 3:** Test performance of the different diagnostic assays used for evaluating *P. falciparum*
 254 infection

		RDT		LM	
		Positive	Negative	Positive	Negative
<i>Var</i> ATS qPCR	Positive	278	534	198	614
	Negative	22	1479	51	1450
Sensitivity (95% CI)		34.24% (30.97 – 37.61)		24.38% (21.47 – 27.49)	
Specificity (95% CI)		98.53% (97.79 – 99.08)		96.60% (95.56 – 97.46)	
PPV % (95% CI)		92.66 (89.20 – 95.08)		79.51 (74.28 – 83.92)	
NPV % (95% CI)		73.48 (72.49 – 74.44)		70.26 (69.41 – 71.09)	
AUC (95% CI)		75.97 (74.17 – 77.69)		71.25 (69.36 – 73.09)	

255 *RDT= Rapid Diagnostic Test; LM= Light Microscopy; PPV= Positive Predictive Value; NPV=*
 256 *Negative Predictive Value; AUC= Area Under the Curve*

257 The limit of detection (LoD), which is defined here as the lowest parasite density that could be
 258 detected with 95% probability, was 1,117 (95% CI: 968–1331) parasites/ μ L for LM and 972
 259 (95% CI: 834–1173) parasites/ μ L for RDT. The LoD of the *var*ATS qPCR method was
 260 previously determined at 0.29 (95% CI: 0.14–2.30) parasites/ μ L (42).

261

262 ***Risk factors for sub-patent infections***

263 Age group, the neighborhood of residency, and absence of fever within 48 hours and at the time
264 of sampling were associated with an increased risk of sub-patent malaria infection by univariate
265 analysis (**Table 4**). All risk factors were tested in the univariate analysis, and only those with
266 $p \leq 0.30$, such as age group, gender, neighborhood of residency, and symptoms, were selected and
267 included in the multivariate analysis. Only age ≥ 15 years (aOR: 1.09; 95% CI: 1.06 - 1.13; $p <$
268 0.0001), the neighborhood of residency, specifically Dar es Salam (aOR: 3.97; 95% CI: 1.91 -
269 8.27; $p < 0.001$), and absence of symptoms (aOR: 2.83; 95% CI: 1.22 - 6.51; $p = 0.015$), were
270 significantly associated with the prevalence of sub-patent infections in multivariable logistic
271 regression analysis. The gender and bed net use did not correlate with sub-patent malaria
272 infection prevalence (all $p > 0.05$) (**Table 4**).

273 **Table 4: Prevalence and risk factors for sub-patent malaria infections in malaria infected individuals (N=863)**

Risk factor	Category	Malaria positive (n=863)	Sub-patent malaria (%)	Univariate cOR [95% CI]	<i>p-value</i>	Multivariate aOR [95% CI]	<i>p-value</i>
Age group	<5	75	27 (36)	1		1	
	5-14	289	117 (40.5)	1.21 [0.71-2.05]	0.479	1.0 [0.90-1.12]	0.922
	≥15	499	349 (69.9)	4.13 [2.49-6.88]	<0.0001	1.09 [1.06-1.13]	<0.0001
Gender	Male	402	218 (54.2)	1	0.108	1	0.294
	Female	461	275 (59.7)	1.25 [0.95-1.64]		1.17 [0.87-1.55]	
Neighborhood	Attienkro	202	95 (47.0)	1		1	
	Belle-ville	105	63 (60.0)	1.69 [1.05-2.73]	0.032	1.19 [1.06-1.33]	0.002
	Sokoura	50	31 (62.0)	1.84 [0.97-3.47]	0.060	1.27 [1.06-1.52]	0.007
	Dar es Salam	58	44 (75.9)	3.54 [1.83-6.86]	<0.001	3.97 [1.91-8.27]	<0.001
	Djézoukouamékro	96	56 (58.3)	1.58 [0.97-2.58]	0.069	1.28 [0.98-1.68]	0.074
	Ngattakro	65	44 (67.7)	2.36 [1.31-4.25]	0.004	1.41 [1.13-1.76]	0.002
	Kennedy	72	46 (63.9)	2.00 [1.14-3.47]	0.015	1.15 [1.05-1.26]	0.004
	Air-France	86	47 (54.7)	1.36 [0.82-2.25]	0.237	1.10 [1.02-1.19]	0.012
	Ngouatanoukro	129	67 (51.9)	1.22 [0.78-1.89]	0.384	1.06 [1.00-1.12]	0.037
Symptoms	Febrile	31	9 (29.0)	1	0.003	1	0.015
	Afebrile	832	484 (58.2)	3.34 [1.5-7.3]		2.83 [1.22-6.51]	
Bed net use (last two weeks)	Every night	489	277 (56.6)	1	0.870	1	0.430
	Sometimes/never	311	178 (57.2)	1.02 [0.77-1.37]		1.13 [0.84-1.53]	

274 cOR: Crude odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval;

275 ***P. falciparum* hrp2/3 deletion typing**

276 A total of 344 *P. falciparum*-positive samples were successfully typed for *hrp2* and *hrp3*
277 deletion. No *hrp2* deletions were observed. Two samples carried *hrp3* deletion/wild-type mixed
278 infections. The first was from an 8-year-old asymptomatic male living in the neighborhood of Air
279 France (health district of Southern Bouaké) who was negative by RDT but positive by LM and
280 qPCR, with a parasite density of 149 parasites/ μ L. The second was from a 9-year-old
281 asymptomatic female from the neighborhood of Ngattakro (health district of Northeastern
282 Bouaké) and was also positive by LM and qPCR only, with a parasite density of 190
283 parasites/ μ L.

284 **Discussion**

285 In 2016, in Bouaké, approximately a third of apparently healthy city dwellers had an
286 asymptomatic malaria infection during the rainy (high transmission) season. More than half of
287 malaria infections were detectable only by highly sensitive PCR (sub-patent infections).
288 Microscopy and rapid diagnostic tests detected fewer than 40% of qPCR-positive infections.
289 While prevalence was high, it was lower than in 2014, when a study conducted in three
290 neighborhoods reported a malaria prevalence of around 80% by microscopy (35). This sharp fall
291 in malaria prevalence between 2014 and 2016 could be attributed to intensive malaria control
292 efforts by the NMCP after the end of the crisis that occurred from 2000 to 2011. Two rounds of
293 large-scale distribution of LLINs were done in 2011 and 2014, leading to a coverage and usage
294 rate of 95% and 68%, respectively (43). In addition, the wide availability of RDTs and
295 artemisinin-combination therapy (ACTs) for testing and treating symptomatic individuals helped
296 decrease the burden of malaria in Bouaké.

297 The prevalence of malaria infection was highly heterogeneous across the neighborhoods, ranging
298 from 15% to more than 55%. Likewise, the prevalence of sub-patent infections also varied across
299 neighborhoods. The ecological environment and *Anopheles* density variability between
300 neighborhoods could be considerable factors that explain this variation. Bouaké is characterized
301 by the presence of lowlands used for agricultural activities, depending on the neighborhood (44).
302 This agricultural activity has been shown to have a significant impact on vector diversity and
303 density (30) and consequently on malaria transmission (28,29), which is highly heterogeneous
304 across neighborhoods.

305 The prevalence of malaria infection was higher in school-age children (5-14 years) compared to
306 younger ones, in line with previous studies (26,45). The high number of malaria infections
307 detected in school-aged children raises concern because they serve as a source of onward parasite
308 transmission (46,47), as this age group has been shown to be the least likely to benefit from
309 universal malaria interventions such as bed nets and access to prompt diagnosis and treatment
310 (48,49). Implementation of strategies that specifically target this age group could help further
311 decrease malaria transmission in this highly endemic area and improve the health of
312 schoolchildren (50–52). The proportion of sub-patent infections was higher in individuals above
313 15 years of age, probably because of greater immunity in older children and adults induced by
314 cumulative exposure to the parasite (53).

315 The sensitivity of LM and RDT is low in areas where a substantial number of asymptomatic and
316 low-density infections are present (54). In this study, the sensitivity of LM and RDTs was 24%
317 and 34%, respectively, as compared to the *varATS* qPCR. Highly sensitive RDTs (55) or loop-
318 mediated isothermal amplification (LAMP) (56) could be promising options to improve the

319 diagnosis of asymptomatic and sub-patent infections in areas where they are common. In
320 Northern Côte d'Ivoire, for example, LAMP has been shown to be a relevant field diagnostic
321 alternative to standard RDTs for identifying asymptomatic infections with a sensibility and
322 specificity of 93.3% (95% CI 85.7–100) and 95.4% (95% CI 92.2–100), respectively (56).

323

324 For the first time in Côte d'Ivoire, parasites were typed for *hrp2/3* deletions. No *hrp2* deletions
325 were detected in the study population, so the use of Pf/*hrp2*-based RDTs for the diagnosis of *P.*
326 *falciparum* is still recommended. Two samples carried an *hrp3*/wild-type mixed infection. *Hrp3*
327 deletion is not a threat for HRP2-based RDTs as long as *hrp2* is present (57). Future monitoring
328 of *hrp2/hrp3* deletion is warranted in samples that are positive by microscopy or LDH-based
329 RDT, but negative by HRP2-based RDT.

330 **Conclusion**

331 The prevalence of *P. falciparum* infection was underestimated when microscopy and RDT were
332 used for diagnosis because a substantial proportion of asymptomatic and sub-patent malaria
333 carriers were present in the population living in the city of Bouaké and could only be diagnosed
334 using the ultra-sensitive PCR diagnostic method (*varATS* qPCR). The prevalence of malaria
335 infection was highly heterogeneous across the city, and older children and adults constitute the
336 reservoirs of the parasite. These hidden parasite reservoirs are a major challenge for the malaria
337 control program in the city. Various strategies, such as intermittent preventive treatment, periodic
338 mass parasite screening and treatment, or mass drug administration, could be suggested to further
339 reduce the burden of malaria in this city. But before that, more follow-up cohort studies will be
340 needed to identify the role of asymptomatic cases in the dynamics of malaria transmission, its

341 seasonal variability, and its contribution to the incidence of malaria in the region, and to provide
342 support in planning an effective and appropriate malaria elimination strategy to implement.

343 **Competing interests**

344 The authors declare that they have no competing interests.

345 **Acknowledgements**

346 We gratefully acknowledge the populations of 9 neighborhoods (DAR, DJZ, NGA, SOK, BLV,
347 ATK, KEN, AIF, and NGO) of Bouaké, especially householders, housewives, guardians of
348 children, and all the technical staff involved in blood sample collection in the field, for their kind
349 support and collaboration. We would also like to thank Mahamadou Barro, PhD student in
350 mathematics, for his invaluable help in analyzing the data.

351 **Authors' contributions**

352 ABS, CK and FR conceived the study, ABS, DFT, SBA, TBN conducted field work and recorded
353 demographic data; YG and CAVA conducted the lab work, ABS analyzed the data and wrote the
354 manuscript. AAK, CR and CK revised the manuscript. All authors read and approved the final
355 manuscript.

356 **References**

- 357 1. World Health Organization. World malaria report 2021: Tracking progress against malaria.
358 Geneva, Switzerland: World Health Organization; 2021.
- 359 2. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability,
360 transmissibility and public health relevance. *Nat Rev Microbiol.* 2014 Dec;12(12):833–40.
- 361 3. Lindblade KA, Steinhardt L, Samuels A, Kachur SP, Slutsker L. The silent threat:
362 asymptomatic parasitemia and malaria transmission. *Expert Review of Anti-infective*
363 *Therapy.* 2013 Jun 1;11(6):623–39.

- 364 4. Okell LC, Ghani AC, Lyons E, Drakeley CJ. Submicroscopic Infection in Plasmodium
365 falciparum-Endemic Populations: A Systematic Review and Meta-Analysis. *The Journal of*
366 *Infectious Diseases*. 2009 Nov 15;200(10):1509–17.
- 367 5. Schneider P, Bousema JT, Gouagna LC, Otieno S, van de Vegte-Bolmer M, Omar SA, et al.
368 Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito
369 infection. *Am J Trop Med Hyg*. 2007 Mar;76(3):470–4.
- 370 6. Coleman RE, Kumpitak C, Ponlawat A, Maneechai N, Phunkitchar V, Rachapaew N, et al.
371 Infectivity of Asymptomatic Plasmodium-Infected Human Populations to Anopheles dirus
372 Mosquitoes in Western Thailand. *Journal of Medical Entomology*. 2004 Mar 1;41(2):201–8.
- 373 7. Gonçalves BP, Kapulu MC, Sawa P, Guelbéogo WM, Tiono AB, Grignard L, et al.
374 Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of
375 differing transmission intensity. *Nat Commun*. 2017 Oct 26;8(1):1133.
- 376 8. Ouédraogo AL, Gonçalves BP, Gnémé A, Wenger EA, Guelbeogo MW, Ouédraogo A, et al.
377 Dynamics of the Human Infectious Reservoir for Malaria Determined by Mosquito Feeding
378 Assays and Ultrasensitive Malaria Diagnosis in Burkina Faso. *J Infect Dis*. 2016 Jan
379 1;213(1):90–9.
- 380 9. Sumner KM, Freedman E, Abel L, Obala A, Pence BW, Wesolowski A, et al. Genotyping
381 cognate Plasmodium falciparum in humans and mosquitoes to estimate onward transmission
382 of asymptomatic infections. *Nat Commun*. 2021 Feb 10;12(1):909.
- 383 10. Conner RO, Dieye Y, Hainsworth M, Tall A, Cissé B, Faye F, et al. Correction to: Mass
384 testing and treatment for malaria followed by weekly fever screening, testing and treatment
385 in Northern Senegal: feasibility, cost and impact. *Malar J*. 2020 Nov 30;19(1):443.
- 386 11. Kim S, Luande VN, Rocklöv J, Carlton JM, Tozan Y. A Systematic Review of the Evidence
387 on the Effectiveness and Cost-Effectiveness of Mass Screen-and-Treat Interventions for
388 Malaria Control. *Am J Trop Med Hyg*. 2021 Sep 7;105(6):1722–31.
- 389 12. Stuck L, Fasih BS, Al-Mafazy AWH, Hofmann NE, Holzschuh A, Grossenbacher B, et al.
390 Malaria infection prevalence and sensitivity of reactive case detection in Zanzibar. *Int J*
391 *Infect Dis*. 2020 Aug;97:337–46.
- 392 13. Hsiang MS, Ntuku H, Roberts KW, Dufour MSK, Whittemore B, Tambo M, et al.
393 Effectiveness of reactive focal mass drug administration and reactive focal vector control to
394 reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-
395 randomised controlled, open-label, two-by-two factorial design trial. *Lancet*. 2020 Apr
396 25;395(10233):1361–73.

- 397 14. Cairns M, Ceesay SJ, Sagara I, Zongo I, Kessely H, Gamougam K, et al. Effectiveness of
398 seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale:
399 Case-control studies in 5 countries. *PLoS Med.* 2021 Sep;18(9):e1003727.
- 400 15. Yimam Y, Mohebalı M, Afshar MJA. Comparison of diagnostic performance between
401 conventional and ultrasensitive rapid diagnostic tests for diagnosis of malaria: A systematic
402 review and meta-analysis. *PLOS ONE.* 2022 févr;17(2):e0263770.
- 403 16. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large
404 proportion of *P. falciparum* isolates in the Amazon region of Peru lack *pfhrp2* and *pfhrp3*:
405 implications for malaria rapid diagnostic tests. *PLoS One.* 2010 Jan 25;5(1):e8091.
- 406 17. Golassa L, Messele A, Amambua-Ngwa A, Swedberg G. High prevalence and extended
407 deletions in *Plasmodium falciparum* *hrp2/3* genomic loci in Ethiopia. *PLoS One.*
408 2020;15(11):e0241807.
- 409 18. Boush MA, Djibrine MA, Mussa A, Talib M, Maki A, Mohammed A, et al. *Plasmodium*
410 *falciparum* isolate with histidine-rich protein 2 gene deletion from Nyala City, Western
411 Sudan. *Sci Rep.* 2020 Jul 30;10(1):12822.
- 412 19. Iriart X, Menard S, Chauvin P, Mohamed HS, Charpentier E, Mohamed MA, et al.
413 Misdiagnosis of imported *falciparum* malaria from African areas due to an increased
414 prevalence of *pfhrp2/pfhrp3* gene deletion: the Djibouti case. *Emerg Microbes Infect.* 2020
415 Dec;9(1):1984–7.
- 416 20. Menegon M, L'Episcopia M, Nurahmed AM, Talha AA, Nour BYM, Severini C.
417 Identification of *Plasmodium falciparum* isolates lacking histidine-rich protein 2 and 3 in
418 Eritrea. *Infect Genet Evol.* 2017 Nov;55:131–4.
- 419 21. Amoah LE, Abuaku B, Bukari AH, Dickson D, Amoako EO, Asumah G, et al. Contribution
420 of *P. falciparum* parasites with *Pfhrp 2* gene deletions to false negative PfHRP 2 based
421 malaria RDT results in Ghana: A nationwide study of symptomatic malaria patients. *PLoS*
422 *One.* 2020;15(9):e0238749.
- 423 22. Bredu DG, Ahadzi GK, Dickson D, Peprah NY, Asamoah A, Asumah GA, et al. Nationwide
424 Surveillance of *Pfhrp2* Exon 2 Diversity in *Plasmodium falciparum* Circulating in
425 Symptomatic Malaria Patients Living in Ghana. *Am J Trop Med Hyg.* 2022 May
426 2;106(6):1660–6.
- 427 23. Assi SB, Ouattara L, Adja AM, Bla KB, N'Cho TB, Lingué KN, et al. Epidemiology of
428 malaria in urban area (Adzopé city, Côte d'Ivoire). *Am-Euras J Sci Res.* 2010;5(2):94–100.
- 429 24. Bassa FK, Ouattara M, Silué KD, Adiossan LG, Baikoro N, Koné S, et al. Epidemiology of
430 malaria in the Taabo health and demographic surveillance system, south-central Côte
431 d'Ivoire. *Malar J.* 2016 Jan 6;15(1):9.

- 432 25. Wang SJ, Lengeler C, Smith TA, Vounatsou P, Cissé G, Tanner M. Rapid Urban Malaria
433 Appraisal (RUMA) III: epidemiology of urban malaria in the municipality of Yopougon
434 (Abidjan). *Malar J*. 2006 Apr 4;5:29.
- 435 26. Gbalégba CGN, Ba H, Silué KD, Ba O, Tia E, Chouaibou M, et al. Distribution of
436 *Plasmodium* spp. infection in asymptomatic carriers in perennial and low seasonal malaria
437 transmission settings in West Africa. *Infect Dis Poverty*. 2018 Apr 25;7:39.
- 438 27. Kouakou KE, Moussa H, Kouassi AM, Goula BTA, Savane I. Redefinition of homogeneous
439 climatic zones in Cote d'Ivoire in a context of climate change. *IJSER*. 2017;8(11):453–62.
- 440 28. Dossou-Yovo J, Doannio JM, Diarrassouba S, Chauvancy G. [The impact of rice fields on
441 malaria transmission in the city of Bouaké, Côte d'Ivoire]. *Bull Soc Pathol Exot*.
442 1998;91(4):327–33.
- 443 29. Dossou-Yovo J, Ouattara A, Doannio JM, Diarrassouba S, Chauvancy G. [Malaria surveys in
444 a humid savannah region in Côte d'Ivoire]. *Med Trop (Mars)*. 1998;58(1):51–6.
- 445 30. Adja AM, Zoh DD, Sagna AB, Kpan DMS, Guindo-Coulibaly N, Yapi A, et al. Diversity of
446 *Anopheles Gambiae* s.l., Giles (Diptera: Culicidae) Larval Habitats in Urban Areas and
447 Malaria Transmission in Bouaké, Côte d'Ivoire. *Vector Borne Zoonotic Dis*. 2021
448 Aug;21(8):593–601.
- 449 31. Ministère de la Santé et de l'Hygiène Publique. Rapport Annuel sur la situation Sanitaire
450 (RASS) 2016. Abidjan, Côte d'Ivoire. 2017;354.
- 451 32. Betsi NA, Koudou BG, Cissé G, Tschannen AB, Pignol AM, Ouattara Y, et al. Effect of an
452 armed conflict on human resources and health systems in Côte d'Ivoire: prevention of and
453 care for people with HIV/AIDS. *AIDS Care*. 2006 May;18(4):356–65.
- 454 33. Adja AM, Yobo MC. Study of malaria transmission risk factors in a time of military-political
455 crisis in Bouake urban area (Ivory Coast). *European Scientific Journal, ESJ [Internet]*. 2015
456 Jan 30 [cited 2022 Nov 3];11(3). Available from:
457 <https://eujournal.org/index.php/esj/article/view/4986>
- 458 34. World Health Organization. World malaria report 2022. Geneva, Switzerland: World Health
459 Organization; 2022.
- 460 35. Assi SB, Ouattara L, Tchiekoi BN, Toure OA, Remoue F, Zika KD, et al. Cross sectional
461 study on prevalence of malaria case and malaria infection in children under 15 years after the
462 military crisis in Bouake, Cte d'Ivoire. *JPVB*. 2022 Jul 31;14(1):8–17.
- 463 36. Camara S, Koffi AA, Ahoua Alou LP, Koffi K, Kabran JPK, Koné A, et al. Mapping
464 insecticide resistance in *Anopheles gambiae* (s.l.) from Côte d'Ivoire. *Parasit Vectors*. 2018
465 Jan 8;11(1):19.

- 466 37. Zoh DD, Ahoua Alou LP, Toure M, Penetier C, Camara S, Traore DF, et al. The current
467 insecticide resistance status of *Anopheles gambiae* (s.l.) (Culicidae) in rural and urban areas
468 of Bouaké, Côte d'Ivoire. *Parasit Vectors*. 2018 Mar 2;11:118.
- 469 38. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive
470 detection of *Plasmodium falciparum* by amplification of multi-copy subtelomeric targets.
471 *PLoS Med*. 2015 Mar;12(3):e1001788.
- 472 39. Koepfli C, Nguitragool W, Hofmann NE, Robinson LJ, Ome-Kaius M, Sattabongkot J, et al.
473 Sensitive and accurate quantification of human malaria parasites using droplet digital PCR
474 (ddPCR). *Sci Rep*. 2016 Dec 16;6:39183.
- 475 40. Oduma CO, Ogolla S, Atieli H, Ondigo BN, Lee MC, Githeko AK, et al. Increased
476 investment in gametocytes in asymptomatic *Plasmodium falciparum* infections in the wet
477 season. *BMC Infect Dis*. 2021 Jan 9;21(1):44.
- 478 41. Vera-Arias CA, Holzschuh A, Oduma CO, Badu K, Abdul-Hakim M, Yukich J, et al. High-
479 throughput *Plasmodium falciparum* hrp2 and hrp3 gene deletion typing by digital PCR to
480 monitor malaria rapid diagnostic test efficacy. *Elife*. 2022 Jun 28;11:e72083.
- 481 42. Holzschuh A, Koepfli C. Tenfold difference in DNA recovery rate: systematic comparison of
482 whole blood vs. dried blood spot sample collection for malaria molecular surveillance. *Malar*
483 *J*. 2022 Mar 15;21:88.
- 484 43. Ministère de la Santé et de l'Hygiène Publique. Plan national de développement sanitaire
485 2016–2020. Abidjan, Côte d'Ivoire. 2016;88.
- 486 44. Dahoui MMC, Adou KA, Coulibaly B, Niamien KL, Koné A, Cornelie S, et al.
487 Entomological drivers of uneven malaria transmission in urban lowland areas in Bouaké,
488 Côte d'Ivoire. *Malaria Journal*. 2023 Jan 31;22(1):34.
- 489 45. Mwesigwa J, Achan J, Di Tanna GL, Affara M, Jawara M, Worwui A, et al. Residual malaria
490 transmission dynamics varies across The Gambia despite high coverage of control
491 interventions. *PLoS One*. 2017;12(11):e0187059.
- 492 46. Walldorf JA, Cohee LM, Coalson JE, Bauleni A, Nkanaunena K, Kapito-Tembo A, et al.
493 School-Age Children Are a Reservoir of Malaria Infection in Malawi. *PLoS One*.
494 2015;10(7):e0134061.
- 495 47. Coalson JE, Cohee LM, Buchwald AG, Nyambalo A, Kubale J, Seydel KB, et al. Simulation
496 models predict that school-age children are responsible for most human-to-mosquito
497 *Plasmodium falciparum* transmission in southern Malawi. *Malar J*. 2018 Apr 3;17(1):147.

- 498 48. Olapeju B, Choiriyyah I, Lynch M, Acosta A, Blaufuss S, Filemyr E, et al. Age and gender
499 trends in insecticide-treated net use in sub-Saharan Africa: a multi-country analysis. *Malaria*
500 *Journal*. 2018 Nov 14;17(1):423.
- 501 49. Coalson JE, Cohee LM, Walldorf JA, Bauleni A, Mathanga DP, Taylor TE, et al. Challenges
502 in Treatment for Fever among School-Age Children and Adults in Malawi. *Am J Trop Med*
503 *Hyg*. 2019 Feb;100(2):287–95.
- 504 50. Cohee LM, Valim C, Coalson JE, Nyambalo A, Chilombe M, Ngwira A, et al. School-based
505 screening and treatment may reduce *P. falciparum* transmission. *Sci Rep*. 2021 Mar
506 25;11(1):6905.
- 507 51. Staedke SG, Maiteki-Sebuguzi C, Rehman AM, Kigozi SP, Gonahasa S, Okiring J, et al.
508 Assessment of community-level effects of intermittent preventive treatment for malaria in
509 schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial. *The Lancet*
510 *Global Health*. 2018 Jun 1;6(6):e668–79.
- 511 52. Tada MS, Ferreira R de GM, Katsuragawa TH, Martha RCD, Costa JDAN, Albrecht L, et al.
512 Asymptomatic infection with *Plasmodium falciparum* and *Plasmodium vivax* in the Brazilian
513 Amazon Basin: to treat or not to treat? *Mem Inst Oswaldo Cruz*. 2012 Aug;107(5):621–9.
- 514 53. Carneiro I, Roca-Feltre A, Griffin JT, Smith L, Tanner M, Schellenberg JA, et al. Age-
515 patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan
516 Africa: a systematic review and pooled analysis. *PLoS One*. 2010 Feb 1;5(2):e8988.
- 517 54. Lo E, Zhou G, Oo W, Afrane Y, Githeko A, Yan G. Low parasitemia in submicroscopic
518 infections significantly impacts malaria diagnostic sensitivity in the highlands of Western
519 Kenya. *PLoS One*. 2015;10(3):e0121763.
- 520 55. Niyukuri D, Sinzinkayo D, Troth EV, Oduma CO, Barendayabo M, Ndereyimana M, et al.
521 Performance of highly sensitive and conventional rapid diagnostic tests for clinical and
522 subclinical *Plasmodium falciparum* infections, and *hrp2/3* deletion status in Burundi. *PLOS*
523 *Global Public Health*. 2022 Jul;2(7):e0000828.
- 524 56. Benié EMA, Silué KD, Ding XC, Yeo I, Assamoi JB, Tuo K, et al. Accuracy of a rapid
525 diagnosis test, microscopy and loop-mediated isothermal amplification in the detection of
526 asymptomatic *Plasmodium* infections in Korhogo, Northern Côte d'Ivoire. *Malar J*. 2022 Apr
527 2;21(1):111.
- 528 57. Kong A, Wilson SA, Ah Y, Nace D, Rogier E, Aidoo M. HRP2 and HRP3 cross-reactivity
529 and implications for HRP2-based RDT use in regions with *Plasmodium falciparum* *hrp2* gene
530 deletions. *Malar J*. 2021 Apr 29;20(1):207.

531

532 **Figure legends**

533 **Figure 1: Study workflow diagram.** Data for analysis consists of participants for whom results
534 from all three tests were available.

535

536 **Figure 2: Distribution of *P. falciparum* infections by the three diagnostic methods.**

537

538 **Figure 3: *P. falciparum* density as determined by *var*ATS qPCR. Panel A shows *P.***

539 *falciparum* density in the whole study population and in samples tested positive (+) or negative


540 (–) by microscopy and/or RDT. **Panel B** shows *P. falciparum* density by age group. Dots

541 represent the parasite density of each participant. Red bars indicate geometric means with 95%

542 confidence intervals. P-values from Dunn’s test with Bonferroni adjustment for multiple pairwise

543 comparisons are given.


medRxiv preprint doi: <https://doi.org/10.1101/2023.11.08.23298263>; this version posted November 9, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure

Whole study population (n=2313)


medRxiv preprint doi: <https://doi.org/10.1101/2023.11.08.23298263>; this version posted November 9, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).





Participants with fever (n=66)



Participants without fever (n=2247)



Figure

A**B**

Figure